MicroRNA 5096: A Drug Target / Disease Biomarker (G100616427)
MicroRNA 5096: A Drug Target / Disease Biomarker
MicroRNA (miRNA) 5096 is a non-coding RNA molecule that plays a critical role in various cellular processes. It is a key regulator of gene expression and has been implicated in a wide range of biological processes, including cell growth, apoptosis, and metabolism.
Recent studies have identified miRNA 5096 as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. miRNA 5096 has also been shown to be involved in several cellular processes that are relevant to these diseases, including the regulation of cell cycle progression, cell survival, and cellular signaling pathways.
One of the key reasons why miRNA 5096 is a promising drug target is its involvement in the regulation of cell cycle progression. MiRNA 5096 has been shown to play a role in the regulation of G1-S transition, a critical step in the cell cycle that involves the entry of cells into the G1 phase and the start of cell growth. Mutations in the miRNA 5096 gene have been shown to lead to altered levels of miRNA 5096 and disrupt the regulation of cell cycle progression.
Another reason why miRNA 5096 is a promising drug target is its involvement in cell survival. miRNA 5096 has been shown to play a role in the regulation of cell survival and has been implicated in the development of cancer. Studies have shown that high levels of miRNA 5096 are associated with poor prognosis in cancer patients and that inhibition of miRNA 5096 has been shown to improve survival in cancer models.
MiRNA 5096 is also involved in the regulation of cellular signaling pathways that are relevant to a wide range of diseases, including neurodegenerative diseases and cardiovascular diseases. For example, miRNA 5096 has been shown to play a role in the regulation of the tau protein, which is a key protein involved in the development of neurodegenerative diseases. Studies have shown that miRNA 5096 levels are associated with increased levels of tau protein and increased neurodegeneration in animal models of neurodegenerative diseases.
In addition to its role in cellular processes, miRNA 5096 has also been shown to be involved in the regulation of inflammation and immune responses. miRNA 5096 has been shown to play a role in the regulation of immune cell function and has been implicated in the development of autoimmune diseases.
Overall, miRNA 5096 is a promising drug target and biomarker due to its involvement in a wide range of cellular processes that are relevant to a variety of diseases. Its potential as a drug target is further supported by its expression levels, which have been shown to be altered in a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the role of miRNA 5096 in these diseases and to develop effective treatments.
Protein Name: MicroRNA 5096
The "MicroRNA 5096 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MicroRNA 5096 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MicroRNA 6087 | MicroRNA 6723 | MicroRNA 7641-1 | MicroRNA 7641-2 | Microtubule-Associated Protein | MICU1 | MICU2 | MICU3 | MID1 | MID1IP1 | MID1IP1-AS1 | MID2 | MIDEAS | MIDEAS-AS1 | MIDN | MIEF1 | MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225
